S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: | Recruiting |
---|---|
Conditions: | Breast Cancer, Brain Cancer, Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases, Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 9/2/2018 |
Start Date: | September 15, 2017 |
End Date: | February 1, 2023 |
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in
patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has
spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat
heart failure and high blood pressure, and it may prevent the heart from side effects of
chemotherapy.
patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has
spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat
heart failure and high blood pressure, and it may prevent the heart from side effects of
chemotherapy.
PRIMARY OBJECTIVES:
I. To assess whether prophylactic beta blocker therapy with carvedilol compared with no
intervention reduces the risk of subsequent cardiac dysfunction in patients with metastatic
breast cancer receiving trastuzumab?based HER-2 targeted therapy.
SECONDARY OBJECTIVES:
I. To assess whether prophylactic beta blocker therapy with carvedilol compared with no
intervention reduces the risk of predefined subsequent cardiac events in patients with
metastatic breast cancer receiving trastuzumab?based HER-2 targeted therapy.
II. To evaluate if prophylactic carvedilol compared with no intervention results in a longer
time to first interruption of trastuzumab?based HER-2 targeted therapy due to either cardiac
dysfunction or events.
III. To assess whether prophylactic beta blocker therapy with carvedilol compared with no
intervention reduces the risk of subsequent cardiac dysfunction OR events in this population.
IV. To establish and prospectively collect a predefined panel of baseline core cardiovascular
measures and develop a predictive model of cardiac dysfunction.
V. To evaluate the rate of cardiac dysfunction in an observational arm consisting of
individuals otherwise eligible for the study except for use of beta blockers, angiotensin
receptor blocker (ARB), or angiotensin converting enzyme (ACE) inhibitors for other medical
reasons.
TERTIARY OBJECTIVES:
I. To evaluate the isoleucine (lle) 655 valine (Val) and and alanine (Ala)ll70 proline (Pro)
single nucleotide polymorphisms (SNPs) of the HER-2 gene as a predictive biomarker of
study-defined cardiac dysfunction.
II. To evaluate plasma neuregulin-1 at baseline and over study time as a predictive biomarker
of study-defined cardiac dysfunction.
III. To evaluate the feasibility of performing serial left ventricular strain in a National
Clinical Trials Network (NCTN) group setting, with the goal of 75% of patients contributing
both a baseline and at least one follow-up strain measurement.
IV. To bank blood for future translational medicine studies such as brain natriuretic peptide
(BNP), additional SNPs, and high sensitivity troponin.
OUTLINE: Patients are randomized to 1 of 2 arms. Patients taking beta blocker, ARB, or ACE
inhibitor at registration are assigned to Arm III.
ARM I: Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive
carvedilol orally (PO) twice daily (BID). Courses repeat every 12 weeks for 108 weeks in the
absence of disease progression or unacceptable toxicity.
ARM II: Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive no
study intervention for up to 108 weeks.
ARM III: Patients undergo observation for up to 108 weeks.
After completion of study, patients are followed up for up to 108 weeks.
I. To assess whether prophylactic beta blocker therapy with carvedilol compared with no
intervention reduces the risk of subsequent cardiac dysfunction in patients with metastatic
breast cancer receiving trastuzumab?based HER-2 targeted therapy.
SECONDARY OBJECTIVES:
I. To assess whether prophylactic beta blocker therapy with carvedilol compared with no
intervention reduces the risk of predefined subsequent cardiac events in patients with
metastatic breast cancer receiving trastuzumab?based HER-2 targeted therapy.
II. To evaluate if prophylactic carvedilol compared with no intervention results in a longer
time to first interruption of trastuzumab?based HER-2 targeted therapy due to either cardiac
dysfunction or events.
III. To assess whether prophylactic beta blocker therapy with carvedilol compared with no
intervention reduces the risk of subsequent cardiac dysfunction OR events in this population.
IV. To establish and prospectively collect a predefined panel of baseline core cardiovascular
measures and develop a predictive model of cardiac dysfunction.
V. To evaluate the rate of cardiac dysfunction in an observational arm consisting of
individuals otherwise eligible for the study except for use of beta blockers, angiotensin
receptor blocker (ARB), or angiotensin converting enzyme (ACE) inhibitors for other medical
reasons.
TERTIARY OBJECTIVES:
I. To evaluate the isoleucine (lle) 655 valine (Val) and and alanine (Ala)ll70 proline (Pro)
single nucleotide polymorphisms (SNPs) of the HER-2 gene as a predictive biomarker of
study-defined cardiac dysfunction.
II. To evaluate plasma neuregulin-1 at baseline and over study time as a predictive biomarker
of study-defined cardiac dysfunction.
III. To evaluate the feasibility of performing serial left ventricular strain in a National
Clinical Trials Network (NCTN) group setting, with the goal of 75% of patients contributing
both a baseline and at least one follow-up strain measurement.
IV. To bank blood for future translational medicine studies such as brain natriuretic peptide
(BNP), additional SNPs, and high sensitivity troponin.
OUTLINE: Patients are randomized to 1 of 2 arms. Patients taking beta blocker, ARB, or ACE
inhibitor at registration are assigned to Arm III.
ARM I: Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive
carvedilol orally (PO) twice daily (BID). Courses repeat every 12 weeks for 108 weeks in the
absence of disease progression or unacceptable toxicity.
ARM II: Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive no
study intervention for up to 108 weeks.
ARM III: Patients undergo observation for up to 108 weeks.
After completion of study, patients are followed up for up to 108 weeks.
Inclusion Criteria:
- STEP 1 REGISTRATION
- Patients must have metastatic breast cancer and be initiating within 7 days of step 1
registration or continuing trastuzumab?based HER-2 targeted therapy without concurrent
anthracyclines in first or second line setting; patients may have brain metastasis;
there is no limit for number of doses of HER-2 targeted therapy prior to registration;
examples of eligible HER-2 targeted therapy:
- Trastuzumab
- Trastuzumab + chemotherapy or hormonal therapy
- Trastuzumab + other HER-2 targeted agent with or without chemotherapy (such as
pertuzumab)
- Ado-trastuzumab (Kadcyla)
- NOTE: Patients on lapatinib without trastuzumab are not eligible; planned
treatment with concurrent HER-2 targeted therapy and anthracyclines is not
permitted
- Patients must be at increased risk for cardiotoxicity defined by at least one of the
following:
- Previous anthracycline exposure, OR
- 1 or more of the following risk factors for heart disease:
- Left ventricular ejection fraction (LVEF) 50-54% by local echocardiography
(ECHO) read
- Age >= 65
- Body mass index (BMI) >= 30 kg/m^2
- Current or prior anti-hypertensive therapy
- Diagnosis of coronary artery disease (CAD)
- Diabetes mellitus
- Atrial fibrillation/flutter
- Patients must not have taken within 21 days prior to step 1 registration, be currently
taking at the time of step 1 registration, or planning to take once registered to step
1 a beta blocker, ARB, or ACE inhibitor in order to be randomized (Arms 1 and 2)
- Patients currently taking a beta blocker, ARB, or ACE inhibitor at the time of
step 1 registration are eligible to register for the non-randomized observational
cohort (Arm 3)
- Patients must not be currently taking or planning to take during study treatment the
following medications:
- B2 agonists
- Bosutinib
- Ceritinib
- Floctafenine
- Methacholine
- Pazopanib
- Rivastigmine
- Vincristine
- Silodosin
- Patients must have a Zubrod Performance status of 0-2
- Patients must have a complete physical examination and medical history within 28 days
prior to registration
- Patients must have LVEF >= 50% by 2-dimensional (D) echocardiogram within 28 days
prior to registration; the echocardiogram must be obtained from a S1501 validated ECHO
laboratory (lab) and submitted for central review by the S1501 ECHO core lab; ECHO
should not be submitted for central read until patient has been otherwise deemed
eligible
- Serum bilirubin < 3.0 x institutional upper limit of normal (IULN)
- Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) and
serum glutamic pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) < 5.0 x IULN
- Patients must have electrocardiogram with corrected QT (QTc) with correction within 28
days prior to registration
- Patients must have a systolic blood pressure >= 80 mm Hg within 14 days prior to
registration
- Patients must not be dialysis dependent
- Patients must be able to swallow tablets
- Patients must not have uncontrolled asthma
- Patients must not co-enroll on other treatment trials
- No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, prostate cancer on
active surveillance, adequately treated stage I or II cancer from which the patient is
currently in complete remission, or any other cancer from which the patient has been
disease free for five years
- Patients must not be pregnant or nursing due to potential fetal or nursing infant
harm; women/men of reproductive potential must have agreed to use an effective
contraceptive method, a woman is considered to be of "reproductive potential" if she
has had menses at any time in the preceding 12 consecutive months; in addition to
routine contraceptive methods, "effective contraception" also includes heterosexual
celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy
prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal
ligation; however, if at any point a previously celibate patient chooses to become
heterosexually active during the time period for use of contraceptive measures
outlined in the protocol, he/she is responsible for beginning contraceptive measures
- Patients must be willing to submit blood specimens
- Sites must seek additional patient consent for the future use of specimens
- Patients must be informed of the investigational nature of this study and must sign
and give written informed consent in accordance with institutional and federal
guidelines
- As a part of the OPEN registration process the treating institution's identity is
provided in order to ensure that the current (within 365 days) date of institutional
review board approval for this study has been entered in the system
- STEP 2 REGISTRATION (Randomization)
- Patients must not be registered to step 2 until receiving confirmation from the ECHO
Core Lab that the patient?s LVEF by echocardiogram was >= 50% by central review;
patients must be registered within 5 calendar days of receiving the e-mail
notification
- Site must verify that there is no known change in the step 1 eligibility since initial
registration
We found this trial at
513
sites
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
Click here to add this to my saved trials
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Virginia G. Kaklamani
Phone: 210-450-3800
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Erin F. Cobain
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Click here to add this to my saved trials
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Joan L. Kramer
Phone: 404-778-1868
Click here to add this to my saved trials
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
Beachwood, Ohio 44122
Principal Investigator: Ayla A. Kessler
Phone: 800-641-2422
Click here to add this to my saved trials
Click here to add this to my saved trials
Bel Air, Maryland 21014
Principal Investigator: Ashkan Bahrani
Phone: 443-643-3010
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Sanford Clinic North-Bemidgi Sanford Health is a voluntary, not-for-profit health care organization. Through its entities,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
Click here to add this to my saved trials
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Bryn Mawr Hospital Bryn Mawr Hospital, a nationally recognized community teaching hospital, is conveniently located...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Burlington, Massachusetts 01805
Principal Investigator: Krishna S. Gunturu
Phone: 781-744-8027
Click here to add this to my saved trials
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
Click here to add this to my saved trials
Click here to add this to my saved trials
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
2600 Sixth St. SW
Canton, Ohio 44710
Canton, Ohio 44710
330.363.4908
Principal Investigator: Sunitha Vemulapalli
Phone: 330-363-6891
Aultman Health Foundation The Aultman Foundation will raise and administer funds in order to support...
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Frank J. Brescia
Phone: 843-792-9321
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1200 West Harrison Stree
Chicago, Illinois 60607
Chicago, Illinois 60607
(312) 996-4350
Principal Investigator: Kent F. Hoskins
Phone: 312-355-3046
Univ of Illinois A major research university in the heart of one of the world's...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
9280 SE Sunnybrook Blvd #100
Clackamas, Oregon 97015
Clackamas, Oregon 97015
(503) 513-3300
Clackamas Radiation Oncology Center State-of-the-art technology and compassionate care come together at Clackamas Radiation Oncology...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials